A Study to Evaluate THR-317 Treatment for Macular Telangiectasia Type 1 (MacTel 1)

Inclusion Criteria: * Male or female aged 18 years or older * Macular oedema caused by MacTel 1, with CST \>300µm on SD-OCT * Written informed consent obtained from the subject prior to screening procedures Exclusion Criteria: * Type 1 or type 2 Diabetes Mellitus * Concurrent disease in the study eye that could require medical or surgical intervention during the study period for up to 30 days after the last study treatment, or could confound interpretation of the results * Previous confounding treatments / procedures, or their planned / expected use during the study period for up to 30 days after the last administration of study treatment * Any active ocular / intraocular infection or inflammation in either eye * Pregnant or lactating female, or female of child-bearing potential not utilising an adequate form of contraception, or male of reproductive potential not utilising contraception